Biocompatible coatings for medical devices
01Overview and value chain
Markers: [EC: MDR 2017/745 | OECD: Biotech-health | Regulator: FDA (USA), EMA (EU), NMPA (China)]
Biocompatible coatings for medical devices are surface treatments applied to catheters, guidewires, stents and other blood- or tissue-contacting devices to reduce friction during insertion, improve blood compatibility, deliver a therapeutic payload, or resist microbial colonization. The confirmed producers here are dedicated coating specialists — companies that formulate, apply and test the coating as a contract service for medical device OEMs, rather than device makers coating their own products in-house. UV-curable chemistry is now the dominant application route across every confirmed producer: Hydromer’s HydrUV platform, Harland Medical Systems’ Lubricent UV and Freudenberg Medical’s LUBRITEQ (launched February 2026) all replace older solvent-based coating processes with a single-step UV cure, a shift driven as much by manufacturing throughput and reduced solvent handling as by coating performance. A second live direction is regulatory-driven reformulation: Biocoat’s Non-PFAS Lumen Coating Method, patented for the inner lumens of catheters, responds directly to tightening PFAS restrictions in the US and EU rather than to a device-performance complaint — the coating chemistry itself is being redesigned around a substance-restriction deadline, not a clinical shortcoming.
The key directions of biocompatible medical device coatings are:
- Hydrophilic lubricious coatings: UV-curable or thermally-cured polymer layers that create a low-friction, water-attracting surface on catheters, guidewires and introducers, the largest and most commoditized segment, sold on lubricity, durability and particulate count rather than a distinct chemistry claim.
- Drug-eluting and drug-delivery coatings: coatings that combine a durable or bioresorbable polymer carrier with a therapeutic payload for tunable elution — from minutes to years — used mainly on cardiovascular stents and drug-coated balloons to limit restenosis.
- Antimicrobial and hemocompatible functional coatings: coatings that add a specific biological function beyond lubricity — infection resistance (Harland’s Bacticent) or reduced thrombus formation (Surmodics’ hemocompatible platform) — for devices with extended blood or tissue contact.
- PFAS-free reformulation: replacement of legacy fluoropolymer-containing lumen coatings with non-PFAS chemistry ahead of tightening US and EU substance restrictions, a compliance-driven reformulation direction distinct from a performance upgrade.
Sectoral value chain
[Coating Chemistry & Formulation] ──> [Substrate Preparation] ──> [Coating Application (Dip/Spray/UV-Cure)] ──> [OEM Device Assembly]
│
(Performance & Biocompatibility Testing)
│
▼
[Regulatory Submission Support]Value chain levels
| Level | Description | Key inputs/outputs |
|---|---|---|
| Coating chemistry and formulation | Developing the proprietary polymer, cross-linker and (where applicable) drug-payload formulation. | In: Base polymers, cross-linkers, active pharmaceutical ingredient. Out: Proprietary coating formulation. |
| Substrate preparation | Preparing the bare device substrate (metal or polymer) to accept the coating. | In: Uncoated device substrate. Out: Primed surface ready for coating. |
| Coating application | Applying the formulation by dip-coating, spray-coating or UV-curing onto the primed substrate. | In: Primed substrate, coating formulation. Out: Coated device component. |
| Performance and biocompatibility testing | Testing friction, particulate generation, adhesion and ISO 10993 biocompatibility. | In: Coated component. Out: Validated performance and biocompatibility data. |
| Regulatory submission support | Supplying test data and master files to support the OEM customer’s FDA 510(k), EU MDR or NMPA submission. | In: Validated test data. Out: Regulatory-submission-ready documentation. |
| OEM device assembly and sterilization | The device OEM assembles the coated component into the finished device and sterilizes it for clinical use. | In: Coated, tested component. Out: Finished, sterilized medical device. |
Cross-cutting technologies of the sector:
- UV-curable single-step coating chemistry: the shared chemistry route across the segment’s leading producers (Hydromer HydrUV, Harland Lubricent UV, Freudenberg LUBRITEQ), replacing older multi-step solvent-based processes with a faster, lower-solvent-handling cure.
- Low-particulate formulation engineering: producers compete substantially on particulate count generated during device insertion, a directly measurable and clinically relevant differentiator across an otherwise similar chemistry base.
- Contract coating as a service model: every confirmed producer coats devices designed and sold by other companies rather than manufacturing finished medical devices itself, positioning the coating specialist as a supplier embedded in the device OEM’s own regulatory submission.
02US
The United States hosts four confirmed coating specialists spanning general hydrophilic lubricious coatings, drug-elution platforms, antimicrobial functional coatings and dedicated coating-application equipment.
Hemocompatible and drug-delivery coating platforms
- Surmodics: a publicly traded (Nasdaq: SRDX) coatings and device-technology company offering medical device drug delivery coatings with durable and bioresorbable polymer platforms tunable from minutes-to-years elution, alongside hemocompatible coatings designed to reduce thrombus formation on blood-contacting devices such as catheters and stents.
Hydrophilic coating specialists for catheters and guidewires
- Biocoat: produces HYDAK hydrophilic coatings for cardiovascular, peripheral vascular and urology devices, and has patented a Non-PFAS Lumen Coating Method for catheter inner lumens in response to tightening PFAS restrictions.
- Hydromer: an ISO 13485-certified coatings specialist offering the HydrUV UV-curable coating platform, anti-thrombogenic coatings, and drug-eluting hydrophilic coatings aimed at reducing coronary restenosis.
- Harland Medical Systems: supplies Lubricent hydrophilic coatings (including the BrightView UV-fluorescing variant for visual coating-coverage verification) and Bacticent antimicrobial coatings, alongside its own Confirm line of coating-testing equipment used to validate friction, thickness and adhesion.
03CN
China is a large and growing market for hydrophilic-coated catheters and guidewires — NMPA product registrations for hydrophilic-coated guidewires and hospital procurement tenders for coated catheters are both active and visible in the domestic market.
Domestic demand without a confirmed domestic vendor
This screening pass could not confirm a China-headquartered coating-technology vendor with its own product page meeting the same own-domain evidence bar applied to the US and EU producers above: the domestic suppliers found in procurement listings and registration databases (including a Hunan-based guidewire maker) surface only through distributor, registry or tender records rather than a vendor-operated product page describing its own coating technology. This section is left descriptive of domestic demand rather than naming an unconfirmed producer; it should be revisited if a China-based coating specialist’s own site can be directly confirmed.
04EU
Europe hosts a vertically integrated contract development and manufacturing organization that added a next-generation hydrophilic coating platform to its device-coating business in 2026.
Vertically integrated hydrophilic coatings from a German CDMO
- Freudenberg Medical: a Germany-headquartered CDMO that launched LUBRITEQ, a single-step UV-curable hydrophilic coating platform, in February 2026, backed by a production-facility expansion of more than $50 million in Aachen, Germany dedicated to drug-device coating capacity.
05Leading companies and research institutes
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Surmodics | 🇺🇸 USA | Drug delivery & hemocompatible coatings | Tunable minutes-to-years elution, thrombus-reducing platform | commercial |
| Biocoat | 🇺🇸 USA | HYDAK hydrophilic coatings | Cardiovascular/urology grade, patented non-PFAS lumen coating | commercial |
| Hydromer | 🇺🇸 USA | HydrUV, anti-thrombogenic, drug-eluting coatings | UV-curable, ISO 13485 certified | commercial |
| Harland Medical Systems | 🇺🇸 USA | Lubricent, Bacticent, Confirm testing line | Chemistry + application equipment + testing, antimicrobial variant | commercial |
| Freudenberg Medical | 🇩🇪 Germany | LUBRITEQ | Single-step UV-curable, vertically integrated CDMO | commercial |
06Tech stack and innovations
The stack centers on UV-curable hydrophilic chemistry as the shared application route, with differentiation coming from functional add-ons (drug elution, antimicrobial action), particulate performance, and — increasingly — substance-restriction-driven reformulation.
- UV-Curable Single-Step Coating as the New Baseline:
- Hydromer’s HydrUV, Harland’s Lubricent UV and Freudenberg’s LUBRITEQ (launched 2026) all replace multi-step solvent-based coating processes with a single UV-cure step, reducing solvent handling and processing time.
- This shift is a manufacturing-economics change as much as a coating-performance one: UV curing lowers per-unit processing cost and solvent-disposal burden for the coating specialist, which is why it has spread across independently confirmed producers rather than remaining one company’s proprietary edge.
- Functional Layering on a Common Hydrophilic Base:
- Producers differentiate largely by what they add to the base hydrophilic layer — a drug payload for elution control (Surmodics), an antimicrobial agent (Harland’s Bacticent), or a fluorescing marker for coating-coverage verification (Harland’s Lubricent BrightView).
- This means evaluating a coating claim requires checking which specific functional layer is present, since the base lubricity chemistry across producers in this category is broadly similar.
- PFAS-Free Reformulation as a Compliance-Driven Innovation Track:
- Biocoat’s patented Non-PFAS Lumen Coating Method reformulates a previously fluoropolymer-dependent coating chemistry to meet tightening PFAS substance restrictions in the US and EU, ahead of a regulatory deadline rather than in response to a device-performance complaint.
- This is a distinct innovation driver from the elution-control and antimicrobial directions above: it is defensive reformulation to preserve market access, not a new clinical claim.
07Value chains and production pipelines
Industrial pipeline of a bio-medical-device-coatings product line
┌───────────────────────────┐ ┌───────────────────────────┐
│ 1. Chemistry & Formulation │ ───> │ 2. Substrate Preparation │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 4. Performance/Biocomp. │ <─── │ 3. Coating Application │
│ Testing │ │ (Dip/Spray/UV-Cure) │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 5. Regulatory Submission │ ───> │ 6. OEM Assembly & │
│ Support │ │ Sterilization │
└───────────────────────────┘ └───────────────────────────┘Stage 1: Coating chemistry and formulation
The coating specialist develops the proprietary polymer, cross-linker and, where applicable, drug-payload formulation, the stage where the specific functional claim (lubricity only, drug elution, antimicrobial action) is engineered in.
Stage 2: Substrate preparation
The bare device substrate, metal or polymer, supplied by the device OEM is primed to accept the coating, a step that must be tailored to the specific substrate material.
Stage 3: Coating application (dip, spray or UV-cure)
The formulation is applied to the primed substrate, increasingly by single-step UV-curing rather than the older multi-step solvent-based dip processes.
Stage 4: Performance and biocompatibility testing
The coated component is tested for friction, particulate generation, adhesion and ISO 10993 biocompatibility, generating the data that substantiates the coating’s specific performance claim.
Stage 5: Regulatory submission support
The coating specialist supplies test data and master files to support the device OEM’s own FDA 510(k), EU MDR or NMPA submission, since the coating is regulated as part of the finished device rather than sold as a standalone regulated product.
Stage 6: OEM device assembly and sterilization
The device OEM assembles the coated component into the finished catheter, guidewire or stent and sterilizes it, the stage where the coating’s friction-reduction, drug-elution or antimicrobial function is delivered to the clinical end user.
| Supplier | Price | Lead time | Certificates | Risk | Confidence |
|---|---|---|---|---|---|
| Surmodics | custom | custom | hydrophilic-coating us | Low | MEDIUM |
| Biocoat | custom | custom | hydrophilic-coating us | Low | HIGH |
| Hydromer | custom | custom | hydrophilic-coating us | Low | HIGH |
| Harland Medical Systems | custom | custom | hydrophilic-coating us | Low | HIGH |
| Freudenberg Medical | custom | custom | hydrophilic-coating eu | Low | HIGH |
Key directions:
- Nearly every confirmed producer has converged on UV-curable, single-step coating chemistry (HydrUV, Lubricent UV, LUBRITEQ) — this replaced older multi-step solvent-based dip processes largely for manufacturing throughput and reduced solvent handling, not primarily for a different coating-performance claim.
- Differentiation between producers is mostly in what functional layer sits on top of a broadly similar hydrophilic base: a drug payload for controlled elution, an antimicrobial agent, or a fluorescing marker for visual coating-coverage verification. Check which specific layer a product carries before comparing two “hydrophilic coating” claims.
- A live, compliance-driven reformulation track is underway: Biocoat’s patented non-PFAS lumen coating responds to tightening PFAS substance restrictions in the US and EU, ahead of a regulatory deadline rather than in response to any performance shortfall in the older fluoropolymer-based chemistry.
Regulatory:
- Every producer here sells the coating as a component embedded in a device OEM’s own submission (FDA 510(k), EU MDR, or China NMPA registration) rather than as a separately regulated product, so buyers should expect a master-file/test-data support relationship, not a standalone regulatory clearance for the coating itself.
- Biocompatibility testing follows the ISO 10993 series across all producers regardless of headquarters region; this is the shared technical baseline behind the FDA/EMA/NMPA markers on this article.
Companies not in table:
- DSM Biomedical and AST (Advanced Surface Technologies) were both screened and dropped: no page on either firm’s own domain, at the domain guessed for AST, could be confirmed as naming the firm alongside a coating product — a genuine unconfirmed case rather than an off-topic exclusion. AST Products, Inc. (Massachusetts, US) turned up separately with a real HydroLAST hydrophilic coating product but was not added to the table this pass since it would duplicate the US region’s producer count without adding a new region.
- Two Chinese candidates (Sinomed and Lepu Medical, both established stent makers) were screened for a dedicated coating-technology business and dropped — the available evidence tied them to finished stent products, not a standalone coating platform or service comparable to the other rows in this table.
- A Hunan-based guidewire maker surfaced repeatedly in Chinese procurement and registration records for hydrophilic-coated guidewires, but only through distributor, registry and tender listings, never a vendor-operated page describing its own coating technology, so it was not added to the table.
Processing note:
- The coating specialists in this table sell to device manufacturers, not directly to hospitals or clinicians — a buyer sourcing a finished coated device should contact the device OEM, not the coating supplier, while a device developer choosing a coating partner should compare functional layer, particulate performance and PFAS status rather than treating “hydrophilic coating” as a single interchangeable category.